Press Resease

Epilepsy Therapeutics Market - Global Industry Analysis

Epilepsy Therapeutics Market by Product Type (First-generation epilepsy therapeutics, Second-generation epilepsy therapeutics, and Third-generation epilepsy therapeutics) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024

Published Date: 07-Aug-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-91 Status : Published

Global epilepsy therapeutics market expected to generate revenue of around USD 5,900 million by end of 2024, growing at a CAGR of around 3.9% between 2018 and 2024. The epilepsy therapeutics market is segmented on the basis of product type, distribution channel, and by geography.

Description

The report covers forecast and analysis for the epilepsy therapeutics market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the epilepsy therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the epilepsy therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the epilepsy therapeutics market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein the product type segment and distribution channel segment are benchmarked based on their market size, growth rate, and general attractiveness.

Global Epilepsy Therapeutics Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, technology and regional expansion of major participants involved in the market on global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to region.

The study provides a decisive view of the epilepsy therapeutics market by segmenting the market based on product type, distribution channel, and regions. All the segments have been analyzed based on present and the future trends and the market is estimated from 2018 to 2024. Based on product type, the market is segmented into first-generation epilepsy therapeutics, second-generation epilepsy therapeutics, and third-generation epilepsy therapeutics. On the basis of the distribution channel, the market is segmented hospital pharmacy, retail pharmacy, and online pharmacy. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further segmented into major countries including the U.S., the U.K., Germany, France, Italy, Spain, China, Japan, India, Brazil, and others. This segmentation includes demand for epilepsy therapeutics market based on each product type and distribution channel in all the regions and countries.

The report also includes detailed profiles of end players such as Eisai Co., Ltd., GlaxoSmithKline, Pfizer Inc., UCB S.A., Sumitomo Dainippon Pharma Co., Ltd., Janssen Pharmaceutical, Abbott, Novartis AG, and Shire.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

This report segments the global epilepsy therapeutics market as follows:

Global Epilepsy Therapeutics Market: Product Type Segment Analysis

  • First-generation epilepsy therapeutics
  • Second-generation epilepsy therapeutics
  • Third-generation epilepsy therapeutics

Global Epilepsy Therapeutics Market: Distribution Channel Segment Analysis

  • Hospital Pharmacy
  • Retail pharmacy
  • Online pharmacy

Global Epilepsy Therapeutics Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Epilepsy Therapeutics market, 2017 - 2024(USD Million)
    • 2.2. Global Epilepsy Therapeutics market: snapshot
  •  
  • Chapter 3. Epilepsy Therapeutics Market- Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Epilepsy Therapeutics market drivers: impact analysis
      • 3.2.2. Increasing prevalence of neurological disorders
      • 3.2.3. Technological advancements
      • 3.2.4. Increasing awareness about diagnostics and treatment of neurological disorders
    • 3.3. Market Restraints
      • 3.3.1. Global Epilepsy Therapeutics market restraints: impact analysis
      • 3.3.2. Restrictive regulations and ethical concerns for drug approval
      • 3.3.3. High cost of Research and development activities
    • 3.4. Opportunities
      • 3.4.1. Rising research & development activity for Epilepsy Therapeutics products
      • 3.4.2. Strong Pipeline
      • 3.4.3. Demand for Advanced Treatment
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by product type segment
      • 3.6.2. Market attractiveness analysis, by Distribution Channel segment
      • 3.6.3. Market attractiveness analysis, by regional segment
    • 3.7. Drug Pipeline Analysis
    • 3.8. Prevalence and Epidemiology : Epilepsy
  •  
  • Chapter 4. Global Epilepsy Therapeutics Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Epilepsy Therapeutics market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Epilepsy Therapeutics Market- Product Type Segment Analysis
    • 5.1. Global Epilepsy Therapeutics market: product overview
      • 5.1.1. Global Epilepsy Therapeutics market revenue share, by product type, 2017 and 2024
    • 5.2. First-generation Epilepsy Therapeutics
      • 5.2.1. Global Epilepsy Therapeutics market for First-generation Epilepsy Therapeutics, 2017 - 2024(USD Million)
      • 5.2.2. Epilepsy Therapeutics, 2017 - 2024(USD Million)
    • 5.3. Second-generation Epilepsy Therapeutics
      • 5.3.1. Global Epilepsy Therapeutics market for Second-generation Epilepsy Therapeutics, 2017 - 2024 (USD Million)
    • 5.4. Third-generation Epilepsy Therapeutics
      • 5.4.1. Global Epilepsy Therapeutics market for Third-generation Epilepsy Therapeutics, 2017 - 2024 (USD Million)
  •  
  • Chapter 6. Global Epilepsy Therapeutics Market- Distribution Channel Segment Analysis
    • 6.1. Global Epilepsy Therapeutics market: form type overview
      • 6.1.1. Global Epilepsy Therapeutics market revenue share, by Distribution Channel, 2017 and 2024
    • 6.2. Hospital Pharmacy
      • 6.2.1. Global Epilepsy Therapeutics market for Hospital Pharmacy, 2017 - 2024 (USD Million)
    • 6.3. Retail Pharmacy
      • 6.3.1. Global Epilepsy Therapeutics market for Retail Pharmacy, 2017 - 2024 (USD Million)
    • 6.4. Online Pharmacy
      • 6.4.1. Global Epilepsy Therapeutics market for Online Pharmacy ,2017 - 2024(USD Million)
  •  
  • Chapter 7. Global Epilepsy Therapeutics Market- Regional Segment Analysis
    • 7.1. Global Epilepsy Therapeutics market: regional overview
      • 7.1.1. Global Epilepsy Therapeutics market revenue share, by region, 2017 and 2024
    • 7.2. North America
      • 7.2.1. North America Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.2.2. North America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.2.3.2. U.S. Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.2.4. Rest of North America
        • 7.2.4.1. Rest of North America Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.2.4.2. Rest of North America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.3.2. Europe Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.3.3. U.K.
        • 7.3.3.1. U.K. Epilepsy Therapeutics market revenue, by product type, 2017 - 2024 (USD Million)
        • 7.3.3.2. U.K. Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024 (USD Million)
      • 7.3.4. U
      • 7.3.5. Germany
        • 7.3.5.1. Germany Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.5.2. Germany Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.3.6. France
        • 7.3.6.1. France Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.6.2. France Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.3.7. Italy
        • 7.3.7.1. Italy Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.7.2. Italy Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.3.8. Spain
        • 7.3.8.1. Spain Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.8.2. Spain Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.3.9. Rest of Europe
        • 7.3.9.1. Rest of Europe Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.9.2. Rest of Europe Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Epilepsy Therapeutics market revenue, by product type, 2017 - 2024 (USD Million)
      • 7.4.2. Asia Pacific Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.4.3. China
        • 7.4.3.1. China Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.3.2. China Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.4.2. Japan Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.4.5. India
        • 7.4.5.1. India Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.5.2. India Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.4.6. Southeast Asia
        • 7.4.6.1. Southeast Asia Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.6.2. Southeast Asia Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.7.2. Rest of Asia Pacific Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.5.2. Latin America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.5.3.2. Brazil Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.5.4. Rest of Latin America
        • 7.5.4.1. Rest of Latin America Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.5.4.2. Rest of Latin America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.6.2. Middle East and Africa Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.6.3. GCC Countries
        • 7.6.3.1. GCC Countries Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.6.3.2. GCC Countries Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
      • 7.6.4. Rest of Middle East and Africa
        • 7.6.4.1. Rest of Middle East and Africa Epilepsy Therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.6.4.2. Rest of Middle East and Africa Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 - 2024(USD Million)
  •  
  • Chapter 8. Company Profile
    • 8.1. Eisai Co., Ltd.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. GlaxoSmithKline
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Pfizer Inc.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. UCB S.A.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Sumitomo Dainippon Pharma Co., Ltd.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Janssen Pharmaceutical
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Abbott
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Novartis AG
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Shire
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments

List of Figures 

1. Market research process
2. Market research methodology
3. Global Epilepsy Therapeutics market revenue, 2017 – 2024 (USD Million) 
4. Porter’s five forces analysis
5. Epilepsy Therapeutics market attractiveness analysis, by product type segment
6. Epilepsy Therapeutics market attractiveness analysis, by Distribution Channel segment
7. Epilepsy Therapeutics market: market attractiveness analysis, by regional segment
8. Company market share analysis, 2017
9. Global Epilepsy Therapeutics market revenue share by product type, 2017 and 2024
10. Global Epilepsy Therapeutics market revenue share by First-generation Epilepsy Therapeutics, 2017 and 2024
11. Global  Epilepsy Therapeutics market revenue share by Second-generation Epilepsy Therapeutics, 2017 and 2024
12. Global  Epilepsy Therapeutics market revenue share by Third--generation Epilepsy Therapeutics, 2017 and 2024
13. Global Epilepsy Therapeutics market revenue share by Distribution Channel, 2017 and 2024
14. Hospital Pharmacy, Epilepsy Therapeutics market revenue share by Distribution Channel, 2017 and 2024
15. Retail Pharmacy, Epilepsy Therapeutics market revenue share by Distribution Channel, 2017 and 2024
16. Online Pharmacy, Epilepsy Therapeutics market revenue share by Distribution Channel, 2017 and 2024
 


List of Tables

1. Epilepsy Therapeutics market: market snapshot                                                                     
2. Drivers of global Epilepsy Therapeutics market: impact analysis 
3. Restraints of global Epilepsy Therapeutics market: impact analysis  
4. North America Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
5. North America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
6. U.S. Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
7. U.S. Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
8. Rest of North America Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
9. Rest of North America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
10. Europe Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
11. Europe Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
12. U.K. Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
13. U.K. Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
14. Germany Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
15. Germany Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
16. France Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
17. France Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
18. Italy Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
19. Italy Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
20. Spain Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
21. Spain Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
22. Rest of Europe Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
23. Rest of Europe Epilepsy Therapeutics market revenue, by Distribution Channel area, 2017 – 2024(USD Million)
24. Asia Pacific Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
25. Asia Pacific Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
26. China Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
27. China Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
28. Japan Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
29. Japan Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
30. India Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
31. India Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
32. Southeast Asia Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
33. Southeast Asia Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
34. Rest of Asia Pacific Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
35. Rest of Asia Pacific Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
36. Latin America Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
37. Latin America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
38. Brazil Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
39. Brazil Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
40. Rest of Latin America Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
41. Rest of Latin America Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
42. Middle East and Africa Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
43. Middle East and Africa Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
44. GCC Countries Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
45. GCC Countries Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
46. South Africa Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
47. South Africa Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
48. Rest of Middle East and Africa Epilepsy Therapeutics market revenue, by product type, 2017 – 2024(USD Million)
49. Rest of Middle East and Africa Epilepsy Therapeutics market revenue, by Distribution Channel, 2017 – 2024(USD Million)
 

Methodology

Free Analysis

Epilepsy is a severe neurological disorder with unpredictable seizures. Epilepsy affects millions of people all over the world and it is the one of the most common neurological disorder. Seizures may be classified as generalized seizures, focal seizures, and other seizures. Among these, focal seizures are the most common type of seizures. Generalized seizures comprise tonic seizures, myoclonic seizures, absences, clonic seizures, and atonic seizures. Focal seizures involve complex partial seizures and secondary generalized clonic/tonic seizures (sGCTS). When a group of nerve cells or neurons in the brain send wrong or multiple signals to the body, at that time seizures occur. The growing prevalence of neurological disorders globally is expected to propel the growth of the global market over the coming years. Moreover, increasing awareness about treatment and diagnostics of neurological disorders and easy availability of drugs in the developed market is expected to propel the growth of the market in the near future.

The global epilepsy therapeutics market is segmented as product type, distribution channel, and by geography. Based on product type, the epilepsy therapeutics market is segmented into first-generation epilepsy therapeutics, second-generation epilepsy therapeutics, and third-generation epilepsy therapeutics. On the basis of the distribution channel, the epilepsy therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

Global Epilepsy Therapeutics Market

North America accounted for the dominant share in the global market for epilepsy therapeutics in 2017 and is anticipated to continue with its regional supremacy over the forthcoming years as well. For epilepsy drugs, North America is the most mature market and hence is expected to grow slowly over the forecast period. The high government support, strong research and development platform, and strong pipeline for epilepsy drugs for the development of next-generation anti-epileptic drugs are the key factors contributing for the high share of North America epilepsy therapeutics market.

Asia Pacific is expected to register the highest CAGR in the global epilepsy therapeutics market in the coming years. The growing awareness about advanced anti-epileptic drug treatment in emerging economies is expected to boost the growth of Asia Pacific epilepsy therapeutics market over the forecast period.  

Some of the key players in the epilepsy therapeutics market are Eisai Co., Ltd., GlaxoSmithKline, Pfizer Inc., UCB S.A., Sumitomo Dainippon Pharma Co., Ltd., Janssen Pharmaceutical, Abbott, Novartis AG, and Shire. The growing prevalence of epilepsy and increasing competition among the key players in the market for the development of advanced drugs is expected to propel the growth of the market over the coming years.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed